Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Sponsor: Guy's and St Thomas' NHS Foundation Trust
Summary
Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.
Official title: Improving Response Assessment in Cancer by Measurement of Cellular Redox Status Using 18F-FSPG Positron Emission Tomography
Key Details
Gender
All
Age Range
16 Years - Any
Study Type
OBSERVATIONAL
Enrollment
32
Start Date
2025-02-19
Completion Date
2027-09
Last Updated
2025-04-04
Healthy Volunteers
No
Interventions
18F-FSPG PET/CT in NSCLC
Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
18F-FSPG PET/CT in HNSCC
Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
Locations (1)
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom